Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks.
Gadde
Kishore M
KM
Obesity Clinical Trials Program, Box 3292, Duke University Medical Center, Durham, NC 27710, USA. gadde001@mc.duke.edu
Allison
David B
DB
D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008019:Life Style; D009765:Obesity / Q000188:drug therapy* / Q000517:prevention & control; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use; D043884:Receptor, Cannabinoid, CB1 / Q000627:therapeutic use*; D000077285:Rimonabant; D012306:Risk; D015431:Weight Loss / Q000187:drug effects*
D019440:Anti-Obesity Agents; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D000077285:Rimonabant